Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
Financial Associated Press, August 18 - Jin Litai announced that since September 1, 2021, the prices of various types of cathodic electrophoretic paint products of the company will rise by 10% - 20%, which shall be subject to the official quotation of the company.
This text is a result of machine translation.
Related companies：
Briefing Dec 19, 2023 10:56 AM
EcoFlow Fined 100 Million Euros from EU, Sources Say
In-depth
Briefing Oct 20, 2023 06:03 PM
· Technology
China’s OpenAI Challenger Zhipu AI Secures Over CNY 2.5 Billion to Step Further on Large-Scale Model
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
May 11, 2023 05:07 PM
Jan 06, 2023 08:30 AM
Briefing Oct 18, 2023 07:02 PM
UAE Bets Big on Renewable Energy, Expects to Invest Over USD 160 Billion in Next 30 Years
Briefing Oct 18, 2023 07:01 PM
Wind Power is Propelled into a New Phase of Extraordinary Growth
Briefing Oct 08, 2023 06:27 PM
Shenzhen Sets Ambitious Goals for Green and Innovative Industries: Aiming for CNY 100 Billion in New Energy Industry Value
Briefing Oct 08, 2023 06:20 PM
Shenzhen Targets 1 Million Kilowatts of Virtual Power Plant Load Regulation by 2025
Financials
Indonesian Rupiah Plunges 1.2% Against USD, Outpacing Ringgit's Decline
Dec 19, 2024 04:59 PM
Consumer Staples
Lack of Trust in AI Tech Leads Singaporean Companies to Cut Investments
Dec 19, 2024 04:50 PM
Briefing Oct 08, 2023 06:15 PM
Shenzhen Accelerates Drive Towards Green Construction: Over 100 Projects to Join Smart Construction Pilot by 2025
Briefing Sep 26, 2023 06:28 PM
SPIC Smart Energy Corporation and Tencent Cloud Officially Signs a Strategic Cooperation Agreement
Briefing Sep 26, 2023 06:27 PM
SVOLT is Poised to Ship 1.6 Million Units Domestically this Year
In-depth
Consumer Discretionary
Amazon Global Selling: A Decade of Growth in a Vast Market
Dec 17, 2024 05:43 PM
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
See more
Read next
Insight
In-depth
Insight
In-depth
Consumer Discretionary
Amazon Global Selling: A Decade of Growth in a Vast Market
Dec 17, 2024 05:43 PM
Insight
In-depth
Consumer Staples · Analysis
Din Tai Fung and the Globalization of Chinese Cuisine
Dec 03, 2024 08:26 PM
Insight
In-depth
Communication · Analysis
Podcast Marketing, A Useful Tool for Companies Going Overseas
Dec 02, 2024 02:15 PM